Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients

Journal of Medical Virology

Volumn 74, Issue 1, 2004, Pages 29-33

  Torti, Carlo ^a   Quiros Roldan, Eugenia ^a   Monno, Laura ^b   Patroni, Andrea ^a,c   Saracino, Annalisa ^d   Angarano, Gioacchino ^d   Tinelli, Carmine ^c   Lo Caputo, Sergio ^e   Tirelli, Valeria ^a   Mazzotta, Francesco ^e   Carosi, Giampiero ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Amprenavir; Drug resistance; HIV 1; Interpretation; Lopinavir

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CROSS RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREVALENCE; RISK FACTOR; TREATMENT FAILURE; VIRUS MUTATION;

AMINO ACID SUBSTITUTION; CARBAMATES; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; GENES, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MULTIVARIATE ANALYSIS; MUTATION; PHENOTYPE; PYRIMIDINONES; REGRESSION ANALYSIS; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 3342913838     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20142     Document Type: Article

References (13)

1. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. 2003. Drug resistance mutations in HIV-1. Top HIV Med 11:92-96.
2. Greenacre M. 1992. Correspondence analysis in medical research. Stat Methods Med Res 1:97-117.
3. Harrigan PR, Montaner JS, Wegner SA, Verbiest W, Miller V, Wood R, Larder BA. 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 15:1671-1677.
4. Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G. 2003. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr 32:268-280.
5. Monno L, Saracino A, Scudeller L, Pastore G, Bonora S, Cargnel A, Carosi G, Angarano G. 2003. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr 33:439-447.
6. Paulsen D, Liao Q, Fusco G, St Clair M, Shaefer M, Ross L. 2002. Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease-inhibitor-experienced patients with HIV viremia. AIDS Res Hum Retroviruses 18: 1011-1019.
7. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT, Martinez-Picado J. 2002. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16:1009-1017.
8. Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, van Laethem K, Smith K, Schapiro JM, Winslow DL, Reid C, Shafer RW. 2003. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr 33:8-14.
9. Saracino A, Angarano G, PhenGen Study Group. 2003. Change of antiretroviral therapy guided by genotypic or phenotypic resistance testing: An open label, randomized, multicentre study (PhenGen). HIV Med 4:176.
10. Scudeller L, Torti C, Quiros-Roldan E, Patroni A, Lo Caputo S, Moretti F, Mazzotta F, Donati E, Vivarelli A, Carosi G. 2003. HIV susceptibility to amprenavir: Phenotype based versus rules-based interpretations. J Antimicrob Chemother 52:776-781.
11. Sugiura W, Matsuda Z, Yokomaku Y, Hertogs K, Larder B, Oishi T, Okano A, Shiino T, Tatsumi M, Matsuda M, Abumi H, Takata N, Shirahata S, Yamada K, Yoshikura H, Nagai Y. 2002. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 46:708-715.
12. Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G, De Gennaro M, Carosi G, Tinelli C. 2003. Comparison between rules-based HIV-1 genotype interpretations and real-phenotype or virtual-phenotype: Concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis 188:194-201.
13. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou R, Israelski D, Zolopa AR, Fessel WJ, Shafer RW. 2003. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 8:4836-4847.